Paper Details

  1. Home
  2. Paper Details

The efficacy and adverse effects of nivolumab and lenvatinib in the treatment of advanced hepatocellular carcinoma.

Author: LaiXiaohuan, WenShilai, YeJianmin, ZengJingke, ZhongLiting

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study compared the efficacy and safety of nivolumab combined with lenvatinib versus lenvatinib alone in treating advanced hepatocellular carcinoma (HCC). The combination therapy resulted in significantly higher objective response rate (45.65% vs 23.91%) and disease control rate (78.26% vs 54.35%) compared to lenvatinib alone. The combination therapy also improved liver function and immune function. While the incidence of adverse reactions was slightly higher in the combination group, it was not statistically significant. Overall, the combination of nivolumab and lenvatinib appears to be a promising treatment option for advanced HCC, offering improved tumor control and quality of life.
Paper Details　
Original Abstract of the Article :
This study intends to investigate nivolumab's efficacy and adverse effects in combination with lenvatinib in treating advanced hepatocellular carcinoma (HCC). For this purpose, ninety-two patients with unresectable advanced HCC admitted were enrolled and were divided into the control group (N=46) an...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.14715/cmb/2022.68.11.10

データ提供：米国国立医学図書館（NLM）

Nivolumab and Lenvatinib: A Double-Edged Sword for Liver Cancer

Hepatocellular carcinoma, or liver cancer, is a formidable foe, like a desert storm. This research examines the combined effectiveness of [nivolumab] and [lenvatinib] in treating [advanced hepatocellular carcinoma]. The authors conducted a study comparing the outcomes of [nivolumab combined with lenvatinib] to [lenvatinib alone]. They investigated whether this combination therapy could offer a more potent weapon against this aggressive cancer. Their findings provide valuable insights into the potential benefits and challenges of this treatment approach.

Fighting Cancer with a Double-Edged Sword

The study revealed that [nivolumab combined with lenvatinib] demonstrated [superior tumor control], leading to a [higher objective response rate] and a [higher disease control rate] compared to [lenvatinib alone]. This suggests that this combination therapy could be a more effective tool for fighting liver cancer. It's like using a double-edged sword in a desert battle, offering a more powerful and versatile weapon against the enemy.

Navigating the Side Effects

While [nivolumab combined with lenvatinib] showed [promise in treating liver cancer], it also [increased the risk of side effects]. It's like navigating a desert landscape, where the path toward victory may be accompanied by challenges and obstacles. The authors emphasize the importance of [close monitoring] and [managing side effects] during treatment. They found that the combination therapy did not significantly affect [liver function], [immune function], or [completion rate] of treatment.

Dr. Camel's Conclusion

This research highlights the potential of nivolumab combined with lenvatinib for treating advanced hepatocellular carcinoma. Like a skilled desert warrior, this combination therapy can offer a more powerful weapon against this aggressive cancer. However, it's important to be aware of the potential side effects and work closely with a medical professional to manage them. It's a reminder that the path to recovery from cancer can be challenging, but with the right tools and support, victory is possible.

Date :
  1. Date Completed 2023-05-01
  2. Date Revised 2023-05-01
Further Info :

Pubmed ID

37114307

DOI: Digital Object Identifier

10.14715/cmb/2022.68.11.10

Related Literature

Article Analysis
・Effects of lenvatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.